Woman´s Health News
-
Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy
Study plans to investigate elinzanetant as non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients Elinzanetant is an innovative non-hormonal development compound in development for the treatment of vasomotor symptoms during menopause Bayer, a global leader in women’s healthcare, announced today that it expands the Phase III clinical ...
By Bayer AG
-
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
The collaboration aims to create standardised, stabilised live microbiota-based formulations addressing bacterial vaginosis (BV), a common vaginal infection among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues1,2,3 The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you